News Highlights: Top Company News of the Day
Pfizer Vaccine Executive Moves to Rival GlaxoSmithKline
The high-profile industry move comes as Pfizer and other vaccine
makers scramble to assess how their shots will stand up to a new
variant of the coronavirus that causes Covid-19.
Facebook Told to Sell Giphy by U.K. Regulator
The U.K.'s top competition regulator directed Meta Platforms,
formerly Facebook, to sell social-media animated-images company
Giphy, saying its acquisition could limit competition among
platforms and U.K. advertisers.
Glencore Faces Call From Activist to Sell Coal Assets
The commodities giant is the last of the world's large miners to
retain a presence in thermal coal, a currently lucrative business
but one seen by some as harmful to the environment.
Zara Parent Elevates Founder's Daughter to Chairwoman
Zara's parent company said it had appointed the daughter of the
retailer's founder as its new chairwoman, placing a little-known
37-year-old atop one of the world's largest fashion chains.
KKR, Wells Fargo Look to Expand at Manhattan's Hudson Yards
High-end office space-with amenities such as outdoor terraces,
game rooms and superior ventilation systems-is still in demand as
companies try to lure back remote workers and retain talent.
SoftBank Bets on Asian Metaverse Platform Selling Digital Gucci, Dior
SoftBank is investing $150 million in a South Korean platform
that has amassed a large following of young female users by selling
high fashion for 3-D avatars.
Covid Antibody Drugs Challenged by Omicron
Regeneron said its antibody drug cocktail was found to lose
effectiveness against the new variant, a sign that some therapies
might need modifying.
GE's Former Appliance Business Thrives Under Chinese Owners
Haier Group bought the business from General Electric in 2016
and has been adding jobs and increasing its U.S. market share.
Sapphire Ventures Extends Fundraising Streak With New $2 Billion Haul
The technology-focused investment firm has been on a fundraising
tear this year after wrapping up a previous drive with $1.7 billion
Merck's Covid-19 Pill to Be Reviewed by FDA Advisers
The panel's endorsement of the antiviral molnupiravir, from
Merck and partner Ridgeback, could open the door for FDA
authorization before the end of the year.
(END) Dow Jones Newswires
November 30, 2021 09:00 ET (14:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.